Cargando…

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jie, Wei, Xiao-yu, Xiang, Jin, Peng, Pai, Xu, Feng-li, Wu, Kang, Luo, Fei-yang, Jin, Ai-shun, Fang, Liang, Liu, Bei-zhong, Wang, Kai, Tang, Ni, Huang, Ai-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2021
Materias:	Full Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639289/ https://www.ncbi.nlm.nih.gov/pubmed/34877393 http://dx.doi.org/10.1016/j.gendis.2021.11.007

Ejemplares similares

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021)

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2021)

The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
por: Li, Gen, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2022)

The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines
por: Yang, Xinyi, et al.
Publicado: (2022)

Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617
por: Fan, Lin-qian, et al.
Publicado: (2021)

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach
por: Ranjan, Prashant, et al.
Publicado: (2022)

Investigation of TNF-α and IL-6 Levels in the Sera of Non-Melanoma Skin Cancer Patients
por: Ghahartars, Mehdi, et al.
Publicado: (2021)

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
por: Augusto, Gilles, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Variant-specific RT-qPCR for rapid screening of B.1.617 mutations in SARS-CoV-2
por: Jallul, Mwada, et al.
Publicado: (2022)

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
por: Wilhelm, Alexander, et al.
Publicado: (2021)

Comparison of the Japan Society of Clinical Chemistry reference method and CDC method for HDL and LDL cholesterol measurements using fresh sera
por: Kayamori, Yuzo, et al.
Publicado: (2021)

Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2)
por: Klimek, Ludger, et al.
Publicado: (2022)

Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach
por: Seadawy, Mohamed G., et al.
Publicado: (2022)

Emerging Variants of B.1.617 Lineage Identified Among Returning Chinese Employees Working in India — Chongqing Municipality, China, April 2021
por: Ye, Sheng, et al.
Publicado: (2021)

Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent
por: Zhang, Meng, et al.
Publicado: (2022)

SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
por: Pascarella, Stefano, et al.
Publicado: (2021)

Characterization of mutations modulating enhanced transmissibility of SARS-CoV-2 B.1.617+ (Delta) variant using In Silico tools
por: Shahhosseini, Nariman
Publicado: (2022)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021)

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
por: Dupont, Liane, et al.
Publicado: (2021)

NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA
por: Francis, Thomas, et al.
Publicado: (1936)

The clinical and immunological features of pediatric COVID-19 patients in China
por: Chen, Juan, et al.
Publicado: (2020)

The surgions mate, 1617
Publicado: (1979)

Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure
por: Hajj-Hassan, Houssein, et al.
Publicado: (2021)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors
por: Müller, Rebecca, et al.
Publicado: (2022)

Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months
por: Peng, Pai, et al.
Publicado: (2021)

High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera
por: Astakhova, E. A., et al.
Publicado: (2022)

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
por: Hu, Jie, et al.
Publicado: (2020)

Correction: Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months
por: Peng, Pai, et al.
Publicado: (2022)

Selectable encapsulated cell quantity in droplets via label-free electrical screening and impedance-activated sorting
por: Zhong, Jianwei, et al.
Publicado: (2023)

Trastuzumab Charge Variants: a Study on Physicochemical and Pharmacokinetic Properties
por: Torkashvand, Fatemeh, et al.
Publicado: (2023)

Differential Expression Profile of ZFX Variants Discriminates Breast Cancer Subtypes
por: Pourkeramati, Fatemeh, et al.
Publicado: (2019)

Detection of Variants of B.1.617 Lineage from Five Returning Chinese Nationals at a Guangxi-Vietnam Border Port — Guangxi Zhuang Autonomous Region, China, April 2021
por: Kang, Ning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aglefe008jel4l21n3lm16jgft